Exelixis (EXEL) Change in Cash (2010 - 2026)
Exelixis (EXEL) recorded quarterly Change in Cash of -$256.3 million in Q2 2026, down 341.4% quarter-over-quarter from $106.2 million in Q1 2026, and down 662.41% on a YoY basis from $45.6 million in Q2 2025.
Exelixis (EXEL) Change in Cash (2010 - 2026) Analysis & Trends
Exelixis' Change in Cash history runs 17 years deep, the most recent figure standing at -$256.3 million for Q2 2026.
- In Q2 2026, Change in Cash fell 662.41% year-over-year to -$256.3 million; the TTM figure through Apr 2026 stood at $42.4 million (up 155.93% YoY), while the FY2026 annual figure was $265.1 million, up 681.14% from the prior year.
- Change in Cash was -$256.3 million for Q2 2026 at Exelixis, down from $106.2 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $211.9 million in Q4 2025 to a low of -$256.3 million in Q2 2026.
- Historically, Change in Cash has averaged -$25.7 million across 5 years, with a median of -$33.6 million in 2025.
- The sharpest annual moves came in 2025 and 2026: Change in Cash sank 879.38% in 2025, then jumped 359.17% in 2026.
- A 5-year view of Change in Cash shows it stood at -$174.1 million in 2022, then increased by 23.11% to -$133.9 million in 2023, then surged by 144.74% to $59.9 million in 2024, then jumped by 253.78% to $211.9 million in 2025, then sank by 220.99% to -$256.3 million in 2026.
- The last three Change in Cash figures came in at -$256.3 million (Q2 2026), $106.2 million (Q1 2026), and $211.9 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 623.00 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -2.44 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 417.10 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -45.97 Mn |
| 10 | Exelixis | 13.72 Bn | 12.95 Bn | 590.86 Mn | -256.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | -256.34 Mn |
| Jan 2, 2026 | 106.19 Mn |
| Oct 3, 2025 | 211.87 Mn |
| Jul 4, 2025 | -19.32 Mn |
| Apr 4, 2025 | -33.62 Mn |
| Jan 3, 2025 | -40.97 Mn |
| Sep 27, 2024 | 59.89 Mn |
| Jun 28, 2024 | -61.10 Mn |
| Mar 29, 2024 | -3.43 Mn |
| Dec 29, 2023 | -133.87 Mn |
| Sep 29, 2023 | -67.62 Mn |
| Jun 30, 2023 | -77.60 Mn |
| Mar 31, 2023 | 39.40 Mn |
| Dec 30, 2022 | -174.09 Mn |
| Sep 30, 2022 | 39.08 Mn |
| Jul 1, 2022 | -99.59 Mn |
| Apr 1, 2022 | 73.39 Mn |
| Dec 31, 2021 | 65.40 Mn |
| Oct 1, 2021 | 59.19 Mn |
| Jul 2, 2021 | 119.38 Mn |